NYSE · Biotech stocks database
IQV — IQVIA Holdings Inc. ☆
IQV (IQVIA Holdings Inc.) stock: $271.75, $44.78B market cap, $2.42B cash, $58.43B EV, $46.04B fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Overview
Catalysts
Assets
Pipeline
Trials
Holders
News
What they do
Our Company IQVIA is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI ® , advanced analytics, the latest technologies and extensive domain expertise.
Source: 10-K FY2025 via SEC EDGAR
Enterprise value
$58,429.4M
Balance sheet
Cash $2,422.0M Debt $16,067.0M Net cash -$13,645.0M Enterprise value $58,429.4M Basic shares 164.8M shares Fully diluted shares 169.4M shares Fully diluted market cap $46,039.6M Cash per share $14.70 Quarterly burn +$182.0M generated
Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.
Share structure
Cap table as of 2025-12-31.
Price history Loading IQV daily closes…
Loading price history…
Next catalyst Oregovomab · Feb 6 - Mar 20 in 13 wks · Phase 3 · Carcinoma, Ovarian Epithelial; Ovarian Neoplasms; Ovarian CancerAll upcoming catalysts (+3 more) →
Upcoming catalysts Expected Drug Phase Indication Mgmt guide Feb 6 - Mar 20 in 13 wks Oregovomab Phase 3 Carcinoma, Ovarian Epithelial; Ovarian Neoplasms; Ovarian Cancer — Mar 13 - Apr 24 in 4 mo Ixovex-1 Phase 2 Solid Tumor; Head and Neck Cancer — Apr 12 - May 24 in 17 mo J147 Emulsion for Injection Phase 2 Acute Ischemic Stroke — Jul 13 - Aug 24 in 20 mo Olorofim Phase 2 Coccidioidomycosis; Disseminated Fungal Infection; Coccidioides Infection —
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Full readout calendar →
Asset data not yet available for this company.
No lead program on file for this company.
Active clinical trials Trial Phase Status Role Sponsor BP Condition(s) Mgmt guide NCT07759544 Not disclosed Not yet recruiting Sponsor IQV — Obesity (Disorder); Overweight , Obesity — NCT04498117 Phase 3 Active, not recruiting Collaborator CanariaBio Inc. — Carcinoma, Ovarian Epithelial; Ovarian Neoplasms; Ovarian Cancer — NCT05908084 Phase 3 Active, not recruiting Collaborator HUMA — End Stage Renal Disease (ESRD) — NCT04877691 Phase 3 Active, not recruiting Collaborator AZN AZN Systemic Lupus Erythematosus — NCT05101187 Phase 3 Active, not recruiting Collaborator F2G Biotech GmbH — Invasive Aspergillosis — NCT05267613 Phase 3 Active, not recruiting Collaborator AZN AZN Erosive Esophagitis — NCT07525427 Phase 2 Recruiting Collaborator Gates Medical Research Institute — Drug Susceptible Pulmonary Tuberculosis — NCT06549946 Phase 2 Recruiting Collaborator Psivac Ltd — Solid Tumor; Head and Neck Cancer — NCT04980638 Phase 2 Recruiting Collaborator EspeRare Foundation — X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) — NCT07430917 Phase 2 Recruiting Collaborator Abrexa Pharmaceuticals, Inc. — Acute Ischemic Stroke — NCT07712484 Phase 2 Not yet recruiting Collaborator F2G Ltd — Coccidioidomycosis; Disseminated Fungal Infection; Coccidioides Infection — NCT02734004 Phase 2 Active, not recruiting Collaborator AZN AZN Ovarian; Breast; SCLC —
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 40 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.
View all 41 active trials for IQVIA RDS Spain, SL on ClinicalTrials.gov
Specialist fund holders Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Fully Diluted · Free biotech stocks database. Figures are sourced from SEC filings and company disclosures; not investment advice.